Chronic obstructive pulmonary disease: An emerging comorbidity in HIV-infected patients in the HAART era?

Infection

Volumn 41, Issue 2, 2013, Pages 347-353

  Madeddu, G ^a   Fois, A G ^a   Calia, G M ^a   Babudieri, S ^a   Soddu, V ^a   Becciu, F ^a   Fiori, M L ^a   Spada, V ^a   Lovigu, C ^a   Mannazzu, M ^a   Caddeo, A ^a   Piras, B ^a   Pirina, P ^a   Mura, M S ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Comorbidity; COPD; HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; ARTICLE; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; COUGHING; CROSS-SECTIONAL STUDY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; RISK FACTOR; SMOKING; SPIROMETRY; TOTAL LUNG CAPACITY; VITAL CAPACITY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RISK FACTORS; RITONAVIR; SMOKING; SPIROMETRY; TOTAL LUNG CAPACITY;

EID: 84879502861     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0330-x     Document Type: Article

References (27)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-9.
3. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Vaeth M, Obel N. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146:87-95.
4. Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; Competence Network for HIV/AIDS. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection. 2011;39:3-12.
5. Leone S, Gregis G, Quinzan G, Velenti D, Cologni G, Soavi L, Ravasio V, Ripamonti D, Suter F, Maggiolo F. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection. 2011;39:13-20.
6. Lazarus JV, Nielsen KK. HIV and people over 50 years old in Europe. HIV Med. 2010;11:479-81.
7. Smith RD, Delpech VC, Brown AE, Rice BD. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS. 2010;24:2109-15.
8. Diaz PT, Wewers MD, Pacht E, Drake J, Nagaraja HN, Clanton TL. Respiratory symptoms among HIV-seropositive individuals. Chest. 2003;123:1977-82.
9. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC; Veterans Aging Cohort 5 Project Team. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006;130:1326-33.
10. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, Rogers RM, Hayashi S, Hogg JC. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164:469-73.
11. US Centers for Disease Control and Prevention (CDC). Health behaviors of adults: United States, 2005-2007. Vital and Health Statistics, Series 10, Number 245, Appendix II, p. 79. 2010. http://www.cdc.gov/nchs/data/series/sr-10/sr10- 245.pdf
12. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581-6.
13. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107-36.
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319-38.
15. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. Updated 2007. Executive summary. 2007. http://www.goldcopd.org/uploads/users/files/ GOLDReport07-0108.pdf.
16. US Centers for Disease Control and Prevention (CDC). Hepatitis B, Chronic Case Definition. 2007. http://www.cdc.gov/osels/ph-surveillance/nndss/casedef/ hepatitisbcurrent.htm.
17. Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Nagaraja HN, Drake J, Clanton TL. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med. 2000;132:369-72.
18. Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Neal D, Nagaraja HN, Drake J, Clanton TL. The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. Am J Respir Crit Care Med. 1999;160:272-7.
19. Yearsley MM, Diaz PT, Knoell D, Nuovo GJ. Correlation of HIV-1 detection and histology in AIDS-associated emphysema. Diagn Mol Pathol. 2005;14:48-52.
20. Diaz PT, Wewers MD, King M, Wade J, Hart J, Clanton TL. Regional differences in emphysema scores and BAL glutathione levels in HIV-infected individuals. Chest. 2004;126:1439-42.
21. Pacht ER, Diaz P, Clanton T, Hart J, Gadek JE. Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time. Chest. 1997;112:785-8.
22. George MP, Kannass M, Huang L, Sciurba FC, Morris A. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One. 2009;4:e6328.
23. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992;146:1067-83.
24. Gingo MR, George MP, Kessinger CJ, Lucht L, Rissler B, Weinman R, Slivka WA, McMahon DK, Wenzel SE, Sciurba FC, Morris A. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med. 2010;182:790-6.
25. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, Oursler KK, Rimland D, Gibert CL, Butt AA, Justice AC. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183:388-95.
26. Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA, Weissman S, Gibert CL, Butt AA, Justice AC. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20:1142-5.
27. Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, Rodriguez-Barradas MC, Wolff MJ, Easterbrook PJ, Clezy K, Slater LN. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178:630-6.